MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories (NASDAQ:MLAB) has announced a quarterly dividend declaration of $0.16 per share of common stock. The dividend will be distributed on June 16, 2025, to shareholders recorded as of May 30, 2025.
Mesa Labs, a global leader in life science tools and critical quality control solutions, serves the pharmaceutical, healthcare, and medical device industries. The company focuses on ensuring product integrity, increasing patient and worker safety, and improving quality of life worldwide through their specialized products and services.
Mesa Laboratories (NASDAQ:MLAB) ha annunciato una dichiarazione di dividendo trimestrale di $0.16 per azione di azioni ordinarie. Il dividendo sarà distribuito il 16 giugno 2025 agli azionisti registrati al 30 maggio 2025.
Mesa Labs, leader globale negli strumenti per le scienze della vita e nelle soluzioni di controllo qualità critico, serve le industrie farmaceutiche, sanitarie e dei dispositivi medici. L'azienda si concentra sull'assicurare l'integrità del prodotto, aumentando la sicurezza dei pazienti e dei lavoratori, e migliorando la qualità della vita in tutto il mondo attraverso i loro prodotti e servizi specializzati.
Mesa Laboratories (NASDAQ:MLAB) ha anunciado una declaración de dividendo trimestral de $0.16 por acción de acciones ordinarias. El dividendo se distribuirá el 16 de junio de 2025 a los accionistas registrados hasta el 30 de mayo de 2025.
Mesa Labs, líder global en herramientas de ciencias de la vida y soluciones críticas de control de calidad, sirve a las industrias farmacéutica, de atención médica y de dispositivos médicos. La empresa se enfoca en garantizar la integridad del producto, aumentar la seguridad de pacientes y trabajadores, y mejorar la calidad de vida en todo el mundo a través de sus productos y servicios especializados.
메사 연구소 (NASDAQ:MLAB)는 보통주 주당 $0.16의 분기 배당금을 선언했다고 발표했습니다. 배당금은 2025년 6월 16일에 배당될 예정이며, 2025년 5월 30일 기준 주주에게 지급됩니다.
메사 연구소는 생명 과학 도구 및 중요한 품질 관리 솔루션의 글로벌 리더로, 제약, 의료 및 의료 기기 산업에 서비스를 제공합니다. 이 회사는 제품의 무결성을 보장하고, 환자 및 근로자의 안전을 높이며, 전문 제품 및 서비스를 통해 전 세계의 삶의 질을 향상시키는 데 집중하고 있습니다.
Mesa Laboratories (NASDAQ:MLAB) a annoncé une déclaration de dividende trimestriel de 0,16 $ par action d'actions ordinaires. Le dividende sera distribué le 16 juin 2025 aux actionnaires enregistrés au 30 mai 2025.
Mesa Labs, leader mondial des outils de sciences de la vie et des solutions critiques de contrôle qualité, sert les industries pharmaceutiques, de santé et de dispositifs médicaux. L'entreprise se concentre sur l'assurance de l'intégrité des produits, l'augmentation de la sécurité des patients et des travailleurs, et l'amélioration de la qualité de vie dans le monde entier grâce à ses produits et services spécialisés.
Mesa Laboratories (NASDAQ:MLAB) hat eine vierteljährliche Dividende von $0,16 pro Aktie der Stammaktien angekündigt. Die Dividende wird am 16. Juni 2025 an Aktionäre ausgezahlt, die bis zum 30. Mai 2025 registriert sind.
Mesa Labs, ein globaler Marktführer in Lebenswissenschaftswerkzeugen und kritischen Qualitätskontrolllösungen, bedient die Pharma-, Gesundheits- und Medizingeräteindustrie. Das Unternehmen konzentriert sich darauf, die Produktintegrität zu gewährleisten, die Sicherheit von Patienten und Arbeitnehmern zu erhöhen und die Lebensqualität weltweit durch ihre spezialisierten Produkte und Dienstleistungen zu verbessern.
- Regular quarterly dividend maintained at $0.16 per share
- Consistent dividend payments demonstrate financial stability
- None.
LAKEWOOD, Colo., April 07, 2025 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of
About Mesa Laboratories, Inc.
Mesa is a global leader in the design and manufacture of life science tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare and medical device industries. Mesa offers products and services to help our customers ensure product integrity, increase patient and worker safety, and improve the quality of life throughout the world.
Forward Looking Statements
This press release may contain information that constitutes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. Forward-looking statements include statements relating to revenues and growth, operating results, profit margin pressure, industry conditions, economic conditions, demand, competition, the effects of additional actions taken to become more efficient or lower costs, risks related to the integration of acquired businesses, changes in legal and regulatory matters, the ability to generate additional cash flow, and any events or developments that we expect or anticipate will occur in the future. Generally, the words “expect,” “anticipate,” “seek,” “intend,” “plan,” “believe,” “could,” “estimate,” “may,” “target,” “project,” and similar expressions identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. These statements are based upon current information and expectations. Actual results may differ materially from those estimated or anticipated as a result of these risks and unknowns or other risks and uncertainties. For additional information concerning these and other risks and uncertainties that could affect these statements, and our business, see our Annual Report on Form 10-K for the year ended March 31, 2024, as well as other risks and uncertainties detailed from time to time in our reports on Forms 10-Q and 8-K subsequently filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof, to provide any updates, or to reflect the occurrence of future events.
CONTACT: Gary Owens; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc., +1-303-987-8000
For more information about the Company, please visit its website at www.mesalabs.com
FAQ
What is the dividend amount and payment date for Mesa Labs (MLAB) Q2 2025?
What is the record date for Mesa Labs' (MLAB) latest dividend?
How much will MLAB shareholders receive per share in the June 2025 dividend?
What industries does Mesa Laboratories (MLAB) serve with its products?
